SuspendedPhase 2

Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients

Mexico40 participantsStarted 2009-11

Plain-language summary

The main objective of this study is to assess the effect of spironolactone on interstitial fibrosis in kidney transplant recipients receiving calcineurin inhibitors

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Kidney Failure * Age \> 18 * Kidney transplant recipients Exclusion Criteria: * Patients taking angiotensin receptor blockers or inhibitors of the angiotensin reconverting enzyme * Kidney transplant performed more than one month from enrollment in the study * Hyperkalemia (K\> 5.5 meqL)

What they're measuring

Interstitial fibrosis in kidney transplant biopsies (time zero biopsy and at 6 months post intervention)

Timeframe: 2 years

Trial details

NCT IDNCT01021943

SponsorInstituto Nacional de Cardiologia Ignacio Chavez

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Kidney Transplant trials